Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

NCT ID: NCT06347003

Last Updated: 2025-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

446 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-22

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Hypertriglyceridemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Plozasiran Injection

4 doses of plozasiran (ARO-APOC3) by subcutaneous (sc) injection

Group Type EXPERIMENTAL

Plozasiran Injection

Intervention Type DRUG

ARO-APOC3 Injection

Placebo

calculated volume to match active treatment by sc injection

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

sterile normal saline (0.9% NaCl)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plozasiran Injection

ARO-APOC3 Injection

Intervention Type DRUG

Placebo

sterile normal saline (0.9% NaCl)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ARO-APOC3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males, or nonpregnant (who do not plan to become pregnant) nonlactating females, who are ≥18 years of age at screening
* Established diagnosis of severe hypertriglyceridemia (SHTG) and prior documented evidence (medical history) of fasting TG levels of ≥ 500 mg/dL (≥5.65mmol/L)
* Mean fasting TG level ≥500 mg/dL (≥5.65 mmol/L) collected at 2 separate and consecutive visits at least 7 days apart and no more than 17 days apart during the screening period
* Fasting low density lipoprotein-cholesterol (LDL-C) ≤130 mg/dL (≤3.37 mmol/L) at screening
* Screening HbA1C ≤9.0%
* Willing to follow diet counseling and maintain a stable low-fat diet
* Must be on standard of care lipid and TG lowering medications per local guidelines (unless documented as intolerant as determined by the Investigator, including an inability to safely administer or re-administer a specific drug because of fear, preference, genetic, clinical, or metabolic considerations, or due to a previous adverse reaction associated with, attributed to, or caused by specific drug)

Exclusion Criteria

* Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within 365 days before Day 1 (except inclisiran, which is permitted). Administration of investigational drug and inclisiran must be separated by at least 4 weeks
* Use of any other hepatocyte-targeted siRNA or antisense oligonucleotide molecule within 60 days or within 5-half-lives before Day 1 based on plasma pharmacokinetics (PK), whichever is longer
* Known diagnosis of familial chylomicronemia syndrome (FCS) (type 1 Hyperlipoproteinemia) by documentation of confirmed homozygote or double heterozygote for loss-of-function mutations in type 1-causing genes
* Acute pancreatitis within 4 weeks prior to screening
* Body mass index \>45kg/m\^2
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Arrowhead Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Center 1

Garden Grove, California, United States

Site Status

Research Center 2

Lake Forest, California, United States

Site Status

Research Center 3

Montclair, California, United States

Site Status

Research Center 4

Panorama City, California, United States

Site Status

Research Center 5

Redding, California, United States

Site Status

Research Center 6

Colorado Springs, Colorado, United States

Site Status

Research Center 7

Hialeah, Florida, United States

Site Status

Research Center 8

Lake City, Florida, United States

Site Status

Research Center 9

Miami Lakes, Florida, United States

Site Status

Research Center 10

Mt. Dora, Florida, United States

Site Status

Research Center 11

Orlando, Florida, United States

Site Status

Research Center 12

Pensacola, Florida, United States

Site Status

Research Center 13

Tamarac, Florida, United States

Site Status

Research Center 14

Tampa, Florida, United States

Site Status

Research Center 15

Macon, Georgia, United States

Site Status

Research Center 16

Savannah, Georgia, United States

Site Status

Research Center 17

Park Ridge, Illinois, United States

Site Status

Research Center 18

Eunice, Louisiana, United States

Site Status

Research Center 19

Baltimore, Maryland, United States

Site Status

Research Center 20

Flint, Michigan, United States

Site Status

Research Center 21

Minneapolis, Minnesota, United States

Site Status

Research Center 22

Olive Branch, Mississippi, United States

Site Status

Research Center 23

Jefferson City, Missouri, United States

Site Status

Research Center 24

St Louis, Missouri, United States

Site Status

Research Center 26

Omaha, Nebraska, United States

Site Status

Research Center 25

Omaha, Nebraska, United States

Site Status

Research Center 27

Las Vegas, Nevada, United States

Site Status

Research Center 29

Long Island City, New York, United States

Site Status

Research Center 30

New York, New York, United States

Site Status

Research Center 31

Rochester, New York, United States

Site Status

Research Center 28

The Bronx, New York, United States

Site Status

Research Center 32

Vestal, New York, United States

Site Status

Research Center 33

Morehead City, North Carolina, United States

Site Status

Research Center 34

Winston-Salem, North Carolina, United States

Site Status

Research Center 35

Cincinnati, Ohio, United States

Site Status

Research Center 36

Columbus, Ohio, United States

Site Status

Research Center 37

Norman, Oklahoma, United States

Site Status

Research Center 38

Oklahoma City, Oklahoma, United States

Site Status

Research Center 39

Powell, Tennessee, United States

Site Status

Research Center 40

El Paso, Texas, United States

Site Status

Research Center 47

Houston, Texas, United States

Site Status

Research Center 45

Houston, Texas, United States

Site Status

Research Center 46

Houston, Texas, United States

Site Status

Research Center 42

Houston, Texas, United States

Site Status

Research Center 44

Houston, Texas, United States

Site Status

Research Center 43

Houston, Texas, United States

Site Status

Research Center 41

Houston, Texas, United States

Site Status

Research Center 48

Laredo, Texas, United States

Site Status

Research Center 49

Missouri City, Texas, United States

Site Status

Research Center 50

Plano, Texas, United States

Site Status

Research Center 51

San Antonio, Texas, United States

Site Status

Research Center 52

Seattle, Washington, United States

Site Status

Research Center 8

Ramos Mejía, Buenos Aires, Argentina

Site Status

Research Center 10

San Isidro, Buenos Aires, Argentina

Site Status

Research Center 7

Temperley, Buenos Aires, Argentina

Site Status

Research Center 4

Córdoba, Córdoba Province, Argentina

Site Status

Research Center 9

Córdoba, Córdoba Province, Argentina

Site Status

Research Center 5

Córdoba, Córdoba Province, Argentina

Site Status

Research Center 3

Córdoba, Córdoba Province, Argentina

Site Status

Research Center 6

Buenos Aires, , Argentina

Site Status

Research Center 2

Buenos Aires, , Argentina

Site Status

Research Center 1

Buenos Aires, , Argentina

Site Status

Research Center 1

Blacktown, New South Wales, Australia

Site Status

Research Center 4

Concord, New South Wales, Australia

Site Status

Research Center 5

Merewether, New South Wales, Australia

Site Status

Research Center 2

Box Hill, Victoria, Australia

Site Status

Research Center 7

Clayton, Victoria, Australia

Site Status

Research Center 3

Heidelberg, Victoria, Australia

Site Status

Research Center 6

Crawley, Western Australia, Australia

Site Status

Research Center 4

Gozée, , Belgium

Site Status

Research Center 6

Hasselt, , Belgium

Site Status

Research Center 3

Mechelen, , Belgium

Site Status

Research Center 2

Namur, , Belgium

Site Status

Research Center 5

Roeselare, , Belgium

Site Status

Research Center 1

Wetteren, , Belgium

Site Status

Research Center 10

Vitória, Espírito Santo, Brazil

Site Status

Research Center 12

Salvador, Estado de Bahia, Brazil

Site Status

Research Center 13

Salvador, Estado de Bahia, Brazil

Site Status

Research Center 14

Salvador, Estado de Bahia, Brazil

Site Status

Research Center 5

Belo Horizonte, Minas Gerais, Brazil

Site Status

Research Center 8

Campina Grande do Sul, Paraná, Brazil

Site Status

Research Center 2

Curitiba, Paraná, Brazil

Site Status

Research Center 4

Belém, Pará, Brazil

Site Status

Research Center 6

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Research Center 9

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Research Center 1

Campinas, São Paulo, Brazil

Site Status

Research Center 7

São Paulo, São Paulo, Brazil

Site Status

Research Center 11

São Paulo, São Paulo, Brazil

Site Status

Research Center 3

Votuporanga, São Paulo, Brazil

Site Status

Research Center 8

Burgas, Burgas, Bulgaria

Site Status

Research Center 11

Rousse, Ruse, Bulgaria

Site Status

Research Center 15

Sofia, Sofia, Bulgaria

Site Status

Research Center 7

Sofia, Sofia, Bulgaria

Site Status

Research Center 12

Blagoevgrad, , Bulgaria

Site Status

Research Center 10

Kardzhali, , Bulgaria

Site Status

Research Center 1

Pleven, , Bulgaria

Site Status

Research Center 3

Pleven, , Bulgaria

Site Status

Research Center 4

Plovdiv, , Bulgaria

Site Status

Research Center 2

Plovdiv, , Bulgaria

Site Status

Research Center 9

Plovdiv, , Bulgaria

Site Status

Research Center 13

Sofia, , Bulgaria

Site Status

Research Center 6

Sofia, , Bulgaria

Site Status

Research Center 5

Sofia, , Bulgaria

Site Status

Research Center 14

Sofia, , Bulgaria

Site Status

Research Center 3

Victoria, British Columbia, Canada

Site Status

Research Center 1

Brampton, Ontario, Canada

Site Status

Research Center 8

London, Ontario, Canada

Site Status

Research Center 2

Sarnia, Ontario, Canada

Site Status

Research Center 5

Waterloo, Ontario, Canada

Site Status

Research Center 6

Montreal, Quebec, Canada

Site Status

Research Center 4

Québec, Quebec, Canada

Site Status

Research Center 7

Halifax, , Canada

Site Status

Research Center 11

Bengbu, Anhui, China

Site Status

Research Center 23

Beijing, Beijing Municipality, China

Site Status

Research Center 22

Beijing, Beijing Municipality, China

Site Status

Research Center 7

Guangzhou, Guangdong, China

Site Status

Research Center 19

Guanzhou, Guangdong, China

Site Status

Research Center 8

Liuzhou, Guangxi Zhuang, China

Site Status

Research Center 13

Xingtai, Hebei, China

Site Status

Research Center 6

Luoyang, Henan, China

Site Status

Research Center 21

Wuhan, Hubei, China

Site Status

Research Center 4

Changsha, Hunan, China

Site Status

Research Center 18

Changsha, Hunan, China

Site Status

Research Center 16

Baotou, Inner Mongolia, China

Site Status

Research Center 10

Suzhou, Jiangsu, China

Site Status

Research Center 9

Shanghai, Shanghai Municipality, China

Site Status

Research Center 12

Shanghai, Shanghai Municipality, China

Site Status

Research Center 2

Yuncheng, Shanxi, China

Site Status

Research Center 17

Chengdu, Sichuan, China

Site Status

Research Center 20

Tianjin, Tianjin Municipality, China

Site Status

Research Center 1

Beijing, Xicheng, China

Site Status

Research Center 15

Wenzhou, Zhejiang, China

Site Status

Research Center 5

Hangzhou, , China

Site Status

Research Center 3

Liaocheng, , China

Site Status

Research Center 14

Nanchang, , China

Site Status

Research Center 1

Zagreb, City of Zagreb, Croatia

Site Status

Research Center 2

Krapinske Toplice, , Croatia

Site Status

Research Center 3

Zagreb, , Croatia

Site Status

Research Center 4

Zagreb, , Croatia

Site Status

Research Center 8

Prague, Prague, Czechia

Site Status

Research Center 4

Prague, Prague, Czechia

Site Status

Research Center 3

Hodonín, , Czechia

Site Status

Research Center 6

Hradec Králové, , Czechia

Site Status

Research Center 1

Ostrava, , Czechia

Site Status

Research Center 7

Praha 1-Nove Mesto, , Czechia

Site Status

Research Center 5

Praha 4-Krc, , Czechia

Site Status

Research Center 2

Uherské Hradiště, , Czechia

Site Status

Research Center 9

Ústí nad Labem, , Czechia

Site Status

Research Center 1

Budapest, , Hungary

Site Status

Research Center 4

Budapest, , Hungary

Site Status

Research Center 2

Budapest, , Hungary

Site Status

Research Center 6

Budapest, , Hungary

Site Status

Research Center 3

Szeged, , Hungary

Site Status

Research Center 5

Veszprém, , Hungary

Site Status

Research Center 3

Rozzano, Milano, Italy

Site Status

Research Center 2

Palermo, Sicily, Italy

Site Status

Research Center 6

Bologna, , Italy

Site Status

Research Center 5

Brescia, , Italy

Site Status

Research Center 4

Milan, , Italy

Site Status

Research Center 1

Roma, , Italy

Site Status

Research Center 15

Żarów, Swidnica, Poland

Site Status

Research Center 7

Bydgoszcz, , Poland

Site Status

Research Center 11

Elblag, , Poland

Site Status

Research Center 10

Katowice, , Poland

Site Status

Research Center 13

Krakow, , Poland

Site Status

Research Center 17

Krakow, , Poland

Site Status

Research Center 8

Krakow, , Poland

Site Status

Research Center 12

Lodz, , Poland

Site Status

Research Center 18

Warsaw, , Poland

Site Status

Research Center 9

Warsaw, , Poland

Site Status

Research Center 16

Wroclaw, , Poland

Site Status

Research Center 14

Wroclaw, , Poland

Site Status

Research Center 3

Brasov, Brașov County, Romania

Site Status

Research Center 1

Bucharest, București, Romania

Site Status

Research Center 2

Cluj-Napoca, Cluj, Romania

Site Status

Research Center 6

Alba Iulia, Jud. Alba, Romania

Site Status

Research Center 4

Ploieşti, Jud. Prahova, Romania

Site Status

Research Center 5

Timișoara, Timiș County, Romania

Site Status

Research Center 8

Deva, , Romania

Site Status

Research Center 7

Galati, , Romania

Site Status

Research Center 9

Târgu Mureş, , Romania

Site Status

Research Center 4

Banská Bystrica, Banská Bystrica Region, Slovakia

Site Status

Research Center 1

Košice, Košice Region, Slovakia

Site Status

Research Center 3

Moldava nad Bodvou, Košice Region, Slovakia

Site Status

Research Center 6

Bardejov, , Slovakia

Site Status

Research Center 5

Bratislava, , Slovakia

Site Status

Research Center 2

Žilina, Žilina Region, Slovakia

Site Status

Research Center 2

Barcelona, , Spain

Site Status

Research Center 3

Barcelona, , Spain

Site Status

Research Center 1

Valencia, , Spain

Site Status

Research Center 4

Zaragoza, , Spain

Site Status

Research Center 3

Torpoint, Cornwall, United Kingdom

Site Status

Research Center 5

Torquay, Devon, United Kingdom

Site Status

Research Center 2

Plymouth, Devpn, United Kingdom

Site Status

Research Center 1

London, , United Kingdom

Site Status

Research Center 4

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Brazil Bulgaria Canada China Croatia Czechia Hungary Italy Poland Romania Slovakia Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-509300-14

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

AROAPOC3-3003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study in Patients With Mixed Dyslipidemia
NCT06497127 ACTIVE_NOT_RECRUITING PHASE2